Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silver zinc sulfadiazine is a topical antimicrobial agent primarily used for the prevention and treatment of wound sepsis in patients with second- and third-degree burns, including partial-thickness burn wounds. It is a combination therapy that integrates the broad-spectrum bactericidal properties of silver sulfadiazine with the wound-healing benefits of zinc. The silver component releases ions into the wound environment that disrupt bacterial cell membranes and bind to microbial DNA, thereby inhibiting bacterial replication and protein synthesis. The zinc component serves as a cofactor for various enzymes involved in tissue repair, promoting epithelialization and accelerating the overall healing process. It is typically formulated as a 1% cream and is often used as a standard of care or comparator in clinical trials evaluating new wound-healing therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silver zinc sulfadiazine.